Generic dossier
Empagliflozin + linagliptin + metformin
25/1000, 12.5/2.5/1000, 10/1000, 5/2.5/1000 mg (as printed) · Tablet · Cardiovascular (as printed)
Product data
- Strength
- 25/1000, 12.5/2.5/1000, 10/1000, 5/2.5/1000 mg (as printed)
- Dosage form
- Tablet
- Dosage-form group
- Oral solid
- Therapeutic area
- Cardiovascular (as printed)
- Market
- EU/US
- Status
- Dossier target · Jun 2027
- Development status
- Pilot bio planned Oct 2026
- Portfolio
- Generic dossier
Note: Strengths and category to be confirmedV-20
Start a conversation
Where does your programme stand?
Tell us the molecule, the dosage form and the market you are filing in. A programme lead will read it and reply with what we would do next.
Business enquiries: vasanthi@kmshc.com · +91 97898 75194V-23